Lawsuit alleges agency is failing to provide documents while rushing to sign 35-year deal with Irish company ‘for reasons ...

Scientists are looking into alternative weight loss solutions beyond GLP-1 medications like Mounjaro, Ozempic and Wegovy ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...

(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...